Phagex

PhageX is a biotechnology company developing a proprietary platform for the creation of universal phages to treat multi-drug resistant bacterial infections and cancer. Unlike traditional phage therapies that are highly strain-specific, PhageX engineers phages to target conserved bacterial receptors, allowing for a broader spectrum of activity against entire species of pathogens. The company's lead programs focus on high-priority threats such as Staphylococcus aureus and Pseudomonas aeruginosa. Additionally, PhageX is exploring the use of oncolytic phages to modulate the tumor microenvironment and enhance anti-tumor immune responses. By leveraging synthetic biology and advanced genomics, the company aims to provide a scalable and effective solution to the global antimicrobial resistance crisis.